Neuphoria Therapeutics (NEUP) Price to Earnings (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Price to Earnings for 4 consecutive years, with 1004.57 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Price to Earnings fell 1675.61% year-over-year to 1004.57 in Q1 2026; TTM through Mar 2026 was 21.4, a 128.72% decrease from a year earlier, with the FY2025 full-year figure at 132.41, down 35.74% from the prior year.
• Price to Earnings was 1004.57 for Q1 2026 at Neuphoria Therapeutics, down from 259.48 in the prior quarter.
• Over five years, Price to Earnings peaked at 1023.52 in Q2 2024 and troughed at 1004.57 in Q1 2026.
• A 4-year average of 243.61 and a median of 220.03 in 2024 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings surged 217.93% in 2025 and tumbled 1675.61% in 2026, its largest moves.
• Over 4 years, Price to Earnings stood at 486.12 in 2023, then soared by 54.74% to 220.03 in 2024, then surged by 217.93% to 259.48 in 2025, then tumbled by 487.15% to 1004.57 in 2026.
• The last three Price to Earnings figures came in at 1004.57 (Q1 2026), 259.48 (Q4 2025), and 148.36 (Q3 2025), per Business Quant data.